For Referring Providers
The following information is for referring providers only.
Use of oral therapy with nirmatrelvir with ritonavir (Paxlovid) is preferred when no contraindications are present. Providers can initiate a request for treatment infusions for ambulatory patients with mild to moderate COVID-19 by completing the site-specific referral form in the Alternatives to Paxlovid section below. Referrals will be reviewed as rapidly as possible.
Alternatives to Nirmatrelvir with Ritonavir (Paxlovid)
For patients who are unable to receive nirmatrelvir with ritonavir (Paxlovid) due to intractable medication interactions or other contraindications, remdesivir is available at BIDMC. Molnupiravir is another oral option for mild-moderate COVID-19 for carefully selected ambulatory patients unable to take nirmatrelvir/ritonavir (Paxlovid) or receive remdesivir.
Providers with WebOMR Access (all three of the following must be completed):
- Place a WebOMR order for COVID-19 Ambulatory Treatment Scheduling.
- Place an order for remdesivir in the WebOMR Infusion/Pheresis Tab.
- Enter a note in WebOMR using the COVID-19 Ambulatory Therapy Referral Assessment Macro.
- Complete a BIDMC COVID-19 Therapeutics Referral form and email the form here or fax to 617-754-8861.
- A telehealth appointment with a BIDMC COVID-19 Therapeutics team provider will be required prior to patient scheduling.